ROLE OF MILK IN COGNITIVE FUNCTION AND QUALITY OF LIFE IN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT A1 protein free milk may provide enhanced outcomes
With
Dr Emma Beckett,
Food & Nutrition Scientist, FOODiQ Global
Professor Stephen Robinson, Psychology Research
Researcher and corresponding author &
semi-retired neuroscientist, RMIT University
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Melbourne and Newcastle, NSW | September 2025
New research emphasises the role of cows’ milk, particularly A1 protein free milk, in enhancing cognitive function and quality of life for older adults with mild cognitive impairment (MCI). A multi-centre, double-blinded, randomised controlled clinical study published in *The Journal of Nutrition, Health and Aging* evaluated 88 milk-tolerant Chinese adults aged 65-75 over three months. Participants consumed either ordinary skim milk or A1 protein free skim milk, leading to improvements in various cognitive assessments.
Both types of milk showed significant enhancements in cognitive performance across multiple tests, including the Subtle Cognitive Impairment Test (SCIT), Montreal Cognitive Assessment (MoCA), and Audio Verbal Learning Test (AVLT).
While both groups reported improvements in quality of life, the A1 protein free group noted greater gains, including a 23% increase in overall quality of life scores and a 43% improvement in memory ability. Despite challenges with vitamin D levels among participants, the study highlights the importance of milk choice in promoting cognitive health, especially for the aging population, where approximately 20% of those over 65 may experience MCI.
Researcher and corresponding author of the clinical study, Professor Stephen Robinson spoke to Australian Health Journal about the findings and the need for further research to confirm these benefits across diverse populations.
Dr Emma Beckett, food and nutrition scientist at FOODiQ, says A1PF milk, as part of a balanced diet, can play a valuable role in improving the nutrition of older adults.
“This is an exciting study because it shows that a small dietary change, adding A1PF milk, may be effective for those experiencing cognitive changes. As Australia’s population continues to age, A1PF milk may offer an accessible way to support overall health and wellbeing, particularly in adults living with MCI,” said Dr Beckett.
Source: Adapted from a2 Milk Australia media release and published study
You Might also like
-
AHW Exhibitor: Gentec Australia
Gentec Australia, an Australian supplier of tapware and designer of wash basins to the healthcare industry exhibited at last week’s Australian Healthcare Week 2019. Their patented basin design reduces the risk of infection through splashing from water through an offset waste, as well as other infection control features. Know My Group reporter Anne Dao spoke with General Manager for Sales Graeme Bunt and State Manager (VIC) Vanessa Beever.
In an upcoming segment Australian Health Journal will cover the technologies deployed and steps taken by hospitals and clinics in infection control.
Post Views:
2,001 -
Thyroid health into pregnancy
‘Without an adequate amount of thyroid hormone mothers can be exposed to hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia or eclampsia, which affect around 10% of pregnant women and are the leading causes of maternal and neonatal mortality worldwide. Mothers who suffer from hypertensive disorders during pregnancy are at increased risk of long-term cardiovascular consequences and hypertensive disorders in subsequent pregnancies. Evidence also indicates a risk of reduced cognitive ability to their offspring.
‘Knowing if you are genetically predisposed to Hashimoto’s or Graves’ Diseases, which are both thyroid autoimmune disorders is important to be aware of, to ensure all appropriate tests are ordered. Autoimmune disorders may predispose mothers to a thyroid problem during pregnancy’, says Professor Creswell Eastman, who also serves as the ATF’s Principal Medical Advisor.
-
Mission to raise awareness of sarcoma and need for clinical trial funding
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.